Research programme: antibacterials - Optimer Pharmaceuticals

Drug Profile

Research programme: antibacterials - Optimer Pharmaceuticals

Alternative Names: Aminoglycosides research programme - Optimer; Antibacterials research programme - Optimer Pharmaceuticals; Macrolides research programme - Optimer; OPT 11; OPT 382; OPT 527

Latest Information Update: 08 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Optimer Pharmaceuticals
  • Class Aminoglycosides; Macrolides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
  • 17 Mar 2004 This programme is available for partnering (http://www.optimerpharma.com)
  • 19 Feb 2004 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top